Last reviewed · How we verify

Opioid administration oxycodone

KK Women's and Children's Hospital · Phase 3 active Small molecule

Oxycodone binds to opioid receptors in the central nervous system to reduce pain perception and provide analgesia.

Oxycodone binds to opioid receptors in the central nervous system to reduce pain perception and provide analgesia. Used for Moderate to severe acute pain, Moderate to severe chronic pain.

At a glance

Generic nameOpioid administration oxycodone
Also known asEpidural Opioid
SponsorKK Women's and Children's Hospital
Drug classOpioid analgesic
TargetMu opioid receptor (OPRM1)
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Oxycodone is a semi-synthetic opioid agonist that binds primarily to mu (μ) opioid receptors in the brain and spinal cord, inhibiting pain signal transmission and modulating pain perception. It also has activity at delta (δ) and kappa (κ) opioid receptors. The drug crosses the blood-brain barrier and produces its analgesic effects through central nervous system depression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: